U.S. Physical Therapy Future Growth

Future criteria checks 3/6

U.S. Physical Therapy is forecast to grow earnings and revenue by 31.8% and 6.2% per annum respectively. EPS is expected to grow by 31.3% per annum. Return on equity is forecast to be 9.9% in 3 years.

Key information

31.8%

Earnings growth rate

31.3%

EPS growth rate

Healthcare earnings growth	17.2%
Revenue growth rate	6.2%
Future return on equity	9.9%
Analyst coverage	Good
Last updated	14 May 2024

Recent future growth updates

Recent updates

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

May 21

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

May 11

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

May 05

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

Apr 21

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Apr 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Mar 04

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Dec 23

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Dec 07

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Oct 13

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

Aug 01

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

Jul 19

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

May 07

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

Apr 16

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Apr 01

Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital

Mar 04

U.S. Physical Therapy beats Q4 top and bottom line estimates; initiates FY23 outlook

Feb 23

U.S. Physical Therapy: Needs To Illustrate Economic Reality Over Accounting Profit

Feb 12

Is Now An Opportune Moment To Examine U.S. Physical Therapy, Inc. (NYSE:USPH)?

Jan 24

We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt

Dec 20

Here's Why We Think U.S. Physical Therapy (NYSE:USPH) Is Well Worth Watching

Dec 05

U.S. Physical Therapy: Not The Most Comfortable Prospect

Nov 09

U.S. Physical Therapy acquires physical therapy practice for $19.3M

Nov 01

U.S. Physical Therapy says Hurricane Ian affected about 50 clinics, ~$395K in lost sales

Oct 17

What Is U.S. Physical Therapy, Inc.'s (NYSE:USPH) Share Price Doing?

Oct 05

U.S. Physical Therapy acquires two-clinic practice

Oct 03

We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt

Sep 03

U.S. Physical Therapy: All Is Not Over, Hold For Now

Aug 26

U.S. Physical Therapy goes ex-dividend tomorrow

Aug 16

Earnings and Revenue Growth Forecasts

NYSE:USPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	725	54	70	74	2
12/31/2025	678	48	69	83	6
12/31/2024	650	42	81	90	4
3/31/2024	606	18	66	75	N/A
12/31/2023	599	18	73	82	N/A
9/30/2023	585	24	64	72	N/A
6/30/2023	575	26	62	70	N/A
3/31/2023	564	28	50	58	N/A
12/31/2022	548	29	50	59	N/A
9/30/2022	536	39	48	57	N/A
6/30/2022	522	38	59	68	N/A
3/31/2022	509	37	61	70	N/A
12/31/2021	490	31	68	76	N/A
9/30/2021	477	31	78	86	N/A
6/30/2021	461	30	81	87	N/A
3/31/2021	418	32	95	101	N/A
12/31/2020	418	32	92	100	N/A
9/30/2020	423	30	82	91	N/A
6/30/2020	431	31	72	82	N/A
3/31/2020	473	29	55	65	N/A
12/31/2019	477	31	52	62	N/A
9/30/2019	472	30	56	65	N/A
6/30/2019	468	23	62	71	N/A
3/31/2019	457	18	63	71	N/A
12/31/2018	449	17	66	73	N/A
9/30/2018	442	18	63	70	N/A
6/30/2018	432	22	58	65	N/A
3/31/2018	421	21	51	58	N/A
12/31/2017	410	22	N/A	57	N/A
9/30/2017	392	20	N/A	53	N/A
6/30/2017	377	20	N/A	42	N/A
3/31/2017	363	21	N/A	51	N/A
12/31/2016	353	21	N/A	51	N/A
9/30/2016	348	20	N/A	48	N/A
6/30/2016	344	21	N/A	49	N/A
3/31/2016	337	21	N/A	49	N/A
12/31/2015	327	21	N/A	38	N/A
9/30/2015	320	21	N/A	45	N/A
6/30/2015	313	20	N/A	43	N/A
3/31/2015	308	20	N/A	45	N/A
12/31/2014	301	19	N/A	41	N/A
9/30/2014	290	19	N/A	45	N/A
6/30/2014	278	18	N/A	45	N/A
3/31/2014	267	18	N/A	44	N/A
12/31/2013	260	18	N/A	45	N/A
9/30/2013	253	18	N/A	39	N/A
6/30/2013	249	18	N/A	41	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: USPH's forecast earnings growth (31.8% per year) is above the savings rate (2.4%).

Earnings vs Market: USPH's earnings (31.8% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: USPH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: USPH's revenue (6.2% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: USPH's revenue (6.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: USPH's Return on Equity is forecast to be low in 3 years time (9.9%).

U.S. Physical Therapy Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 9.0% to US$119

Price target decreased by 9.6% to US$110

Consensus EPS estimates fall by 10%

Price target decreased by 7.9% to US$118

Price target increased by 7.9% to US$119

Price target increased by 7.5% to US$110

Recent updates

Chairman & CEO notifies of intention to sell stock

Chairman & CEO recently sold US$212k worth of stock

There May Be Reason For Hope In U.S. Physical Therapy's (NYSE:USPH) Disappointing Earnings

Chief Operating Officer - East recently sold US$261k worth of stock

U.S. Physical Therapy (NYSE:USPH) Is Due To Pay A Dividend Of $0.44

First quarter dividend of US$0.44 announced

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Returns On Capital Signal Tricky Times Ahead For U.S. Physical Therapy (NYSE:USPH)

A Look At The Fair Value Of U.S. Physical Therapy, Inc. (NYSE:USPH)

U.S. Physical Therapy, Inc., Annual General Meeting, May 21, 2024

Is Now The Time To Look At Buying U.S. Physical Therapy, Inc. (NYSE:USPH)?

Executive VP recently sold US$213k worth of stock

Executive VP notifies of intention to sell stock

Price target increased by 9.0% to US$119

Chief Operating Officer - West recently sold US$274k worth of stock

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Shareholders Might Be Looking For Exit

Upcoming dividend of US$0.44 per share

Fourth quarter dividend increased to US$0.44

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Increases Quarterly Dividend, Payable on April 5, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

U.S. Physical Therapy, Inc. to Report Q4, 2023 Results on Feb 28, 2024

The Returns On Capital At U.S. Physical Therapy (NYSE:USPH) Don't Inspire Confidence

Why U.S. Physical Therapy, Inc. (NYSE:USPH) Could Be Worth Watching

Now 20% undervalued after recent price drop

Price target decreased by 9.6% to US$110

Consensus EPS estimates fall by 10%

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on December 8, 2023

Price target decreased by 7.9% to US$118

Now 20% undervalued after recent price drop

U.S. Physical Therapy, Inc. to Report Q3, 2023 Results on Nov 07, 2023

U.S. Physical Therapy: Positioned For Market Dominance Amidst Attractive Valuations

Is U.S. Physical Therapy (NYSE:USPH) A Risky Investment?

U.S. Physical Therapy (NYSE:USPH) Could Be Struggling To Allocate Capital

Chief Operating Officer - West recently sold US$452k worth of stock

Should You Think About Buying U.S. Physical Therapy, Inc. (NYSE:USPH) Now?

Chief Operating Officer - West notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations

U.S. Physical Therapy, Inc. Declares Quarterly Dividend, Payable on September 8, 2023

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired a 70% stake in U.S. Physical Therapy, Inc. (NYSE:USPH) for $2.1 million.

Are U.S. Physical Therapy, Inc. (NYSE:USPH) Investors Paying Above The Intrinsic Value?

U.S. Physical Therapy, Inc. to Report Q2, 2023 Results on Aug 08, 2023

U.S. Physical Therapy: Bolt-On Strategy Scaling Earnings Power (Rating Upgrade)

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 75% interest in Physical therapy practice with four clinics for $3.1 million

U.S. Physical Therapy, Inc. has completed a Follow-on Equity Offering in the amount of $150.00003 million.

Price target increased by 7.9% to US$119

U.S. Physical Therapy, Inc. Elects Nancy Ham to the Board of Directors

Upcoming dividend of US$0.43 per share at 1.6% yield

At US$114, Is U.S. Physical Therapy, Inc. (NYSE:USPH) Worth Looking At Closely?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

U.S. Physical Therapy Declares Quarterly Dividend, Payable on June 9, 2023

U.S. Physical Therapy, Inc.'s (NYSE:USPH) Intrinsic Value Is Potentially 25% Below Its Share Price

U.S. Physical Therapy (NYSE:USPH) Has A Pretty Healthy Balance Sheet

Independent Director recently sold US$463k worth of stock

Executive VP recently sold US$92k worth of stock

Some Investors May Be Worried About U.S. Physical Therapy's (NYSE:USPH) Returns On Capital

Upcoming dividend of US$0.43 per share at 1.7% yield

Price target increased by 7.5% to US$110

Full year 2022 earnings: EPS misses analyst expectations

U.S. Physical Therapy beats Q4 top and bottom line estimates; initiates FY23 outlook

U.S. Physical Therapy: Needs To Illustrate Economic Reality Over Accounting Profit

U.S. Physical Therapy, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now An Opportune Moment To Examine U.S. Physical Therapy, Inc. (NYSE:USPH)?

Independent Director recently sold US$608k worth of stock

We Think U.S. Physical Therapy (NYSE:USPH) Can Stay On Top Of Its Debt

President recently sold US$900k worth of stock

Here's Why We Think U.S. Physical Therapy (NYSE:USPH) Is Well Worth Watching

U.S. Physical Therapy, Inc. (NYSE:USPH) acquired 80% stake in Thirteen-clinic physical therapy practice from practice’s owners for $25 million.